TABLE 2

Cox regression analysis of HLA class I effects on progression to clinical diabetes in children with diabetes-associated autoantibodies when categorized according to presence of DR3/DR4 class II combination

Follow-up from appearance of first biochemically defined autoantibody*
Multivariate analysis
DR3/4 not presentDR3/4 present
HLA-A*030.0150.490 (0.276–0.870)0.7411.142 (0.518–2.518)
HLA-A*240.0961.643 (0.915–2.948)0.1420.372 (0.099–1.391)
HLA-B*390.6601.208 (0.520–2.805)0.0046.564 (1.801–23.926)
Follow-up from appearance of second biochemically defined autoantibody
Multivariate analysis
DR3/4 not presentDR3/4 present
HLA-A*030.0030.388 (0.208–0.724)0.5541.310 (0.535–3.206)
HLA-A*240.2521.455 (0.766–2.765)0.1170.297 (0.065–1.356)
HLA-B*390.0133.160 (1.279–7.806)0.0077.454 (1.740–31.928)
  • Data are P values and hazard ratio for diabetes progression (95% CI).

  • *Stratified according to age at appearance of first biochemically defined autoantibody.

  • †Stratified according to age at appearance of second biochemically defined autoantibody.